http://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Thu, 23 Nov 2017 05:18:46 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial ]]> http://www.proactiveinvestors.com.au/companies/news/182503/actinogen-medical-enrols-first-uk-patient-in-alzheimers-therapy-trial-182503.html Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

The patient in UK was enrolled at St. Pancras Clinical Research in London. This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open.

Actinogen’s trial will enrol 174 patients at 20 research sites across Australia, the U.S. and the UK.

To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial.

The first XanADu patient will complete the study next month, having reached the end of the 12-week dosing period, and now entering the 4-week follow up phase of the trial.

It is estimated that there are nearly 50 million people with Alzheimer’s disease worldwide, increasing to 131 million by 2050, making it critical to find effective new drugs to treat the disease.

The progress in the development of Xanamem is expected to provide an opportunity for Actinogen to make a profound difference to Alzheimer’s patients and their carers worldwide.

Actinogen ended the June quarter with $3.98 million in cash.

]]>
Wed, 16 Aug 2017 13:11:00 +1000 http://www.proactiveinvestors.com.au/companies/news/182503/actinogen-medical-enrols-first-uk-patient-in-alzheimers-therapy-trial-182503.html
<![CDATA[News - Actinogen Medical begins landmark Alzheimer’s disease clinical trial ]]> http://www.proactiveinvestors.com.au/companies/news/177831/actinogen-medical-begins-landmark-alzheimers-disease-clinical-trial-177831.html Actinogen Medical (ASX:ACW) has reached a major milestone with the first patient treated in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease.

Xanamem has been specifically designed to block the production of excess cortisol in the brain.

Cortisol is a hormone produced by the body in times of stress and there is a growing body of research that shows a strong association between excess cortisol and Alzheimer’s disease. 

This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University and Actinogen.

The first patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia.

Other trial sites in Australia, the U.S. and the UK will soon start recruiting patients, with the final patient expected by Q4 2018, and top-line results for the trial expected in Q1 2019.

Xanamem represents a potential breakthrough in treating Alzheimer’s disease at a time when several high-profile drug trials based on more traditional approaches have failed.

XanADu, the largest global Alzheimer’s dementia study ever conducted by an Australian biotech company, will enrol 174 patients at 20 research sites across Australia, the UK and the U.S.

In the U.S. alone, the cost of managing Alzheimer’s disease is estimated to be US$250 billion, and is set to increase to US$2 trillion by 2050, outstripping the treatment costs of all other diseases.

]]>
Tue, 16 May 2017 10:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/177831/actinogen-medical-begins-landmark-alzheimers-disease-clinical-trial-177831.html
<![CDATA[News - Actinogen Medical on track to begin Alzheimer’s disease trial ]]> http://www.proactiveinvestors.com.au/companies/news/172966/actinogen-medical-on-track-to-begin-alzheimers-disease-trial-172966.html Actinogen Medical (ASX:ACW) has received the approval in the UK to conduct its Phase II clinical trial of Xanamem™ for mild Alzheimer’s disease.

The trial was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) following the regulatory approval received from the FDA in the U.S. in January 2017.

These approvals provide a strong endorsement of Actinogen’s progress towards the treatment of Alzheimer’s and underscores the quality of Actinogen's existing research data on Xanamem.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

Raised cortisol has been strongly associated with Alzheimer’s disease and lowering cortisol in the brain is an important new target for treating Alzheimer’s disease.

Actinogen will conduct the Phase II double-blind, 12-week study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease.

The company will enrol 174 patients at research sites across the UK, U.S. and Australia as part of the trial.

Inhibiting the production of cortisol in the brain with Xanamem could have a major impact on the wellbeing of people living with dementia as well as those at high risk of developing this condition.

Actinogen expects to shortly receive approval from the Australian Therapeutic Goods Administration
(TGA) to conduct the trial in Australia.

This will be the last major regulatory approval required before the company can begin actively recruiting.

Actinogen’s share price has increased by more than 53% during the past three months, last trading at $0.06.

The company is well funded with a cash balance of circa $5.8 million as at 31 December 2016.

]]>
Fri, 10 Feb 2017 05:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/172966/actinogen-medical-on-track-to-begin-alzheimers-disease-trial-172966.html
<![CDATA[News - Actinogen Medical in an ASX trading halt ]]> http://www.proactiveinvestors.com.au/companies/news/171024/actinogen-medical-in-an-asx-trading-halt-171024.html Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

The halt will remain in place until the opening of trade on Wednesday 4th January 2017, or earlier if an announcement is made to the market.

]]>
Fri, 30 Dec 2016 09:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/171024/actinogen-medical-in-an-asx-trading-halt-171024.html
<![CDATA[News - Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study ]]> http://www.proactiveinvestors.com.au/companies/news/147785/actinogen-medical-ltd-to-enhance-safety-profile-of-alzheimers-drug-study-69104.html Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA.

The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug.

The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

An enhanced protocol will be detemined with both Australian and U.K. regulators and hospital sites, with patients expected to be enrolled in the second half of 2016.

Importantly, a U.S. focused study and protocol design will allow for broader value creation, as the U.S. is the largest market for Alzheimer’s drugs.

Xanamem has been specifically designed to inhibit the excess production of cortisol, the ‘stress hormone’ in the brain.

Recent global research has demonstrated that excess cortisol is associated with cognitive decline and neurotoxicity in the brain, which are the hallmarks of Alzheimer’s disease.

In 2015 the total estimated global cost of treating Alzheimer’s was close to US$1 trillion.

The potential upside for a successful drug is significant, which has helped Actinogen share price almost double during the last six months.

The phase II study is fully funded through to completion with $6.8 million cash as on 31 March 2016.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 09 Jun 2016 09:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147785/actinogen-medical-ltd-to-enhance-safety-profile-of-alzheimers-drug-study-69104.html
<![CDATA[News - Actinogen Medical on track with Alzheimer drug trial ]]> http://www.proactiveinvestors.com.au/companies/news/147784/actinogen-medical-on-track-with-alzheimer-drug-trial-64926.html Alzheimer’s disease drug developer Actinogen Medical (ASX:ACW) is on a path to the second critical phase of its clinical trial with its promising new treatment for patients with alzheimer's dementia.

Its novel drug compound Xanamen targets the enzyme 11beta-HSD1 blocking production of excess cortisol and negative effects of elevated levels.

The trial which is being conducted in Perth saw Xanamen effectively delivered by oral administration to the brain in doses that are predicted to inhibit the 11beta-HSD1 enzyme in the brain in patients.

Cortisol is known as the “stress hormone”, and excess cortisol in the brain is associated with memory loss, amyloid plaquing and neural death, the hallmarks of Alzheimer’s disease.

With the results, Actinogen Medical will move to a Phase II trial to demonstrate the effectiveness of Xanamem in treating patients suffering from mild Alzheimer’s disease.

The second phase of the trial will treat around 200 patients in Australia, the UK and the USA, under a U.S. Food & Drug Administration (FDA) approved Investigational New Drug (IND).

The prize for a successful drug is significant with a multi-billion dollar market potential. The cost of alzheimer’s treatment in the US alone was estimated to be US$250 billion in 2013, with this cost estimated to increase to US$1 trillion by 2050.

Alzheimer’s disease is now the second leading cause of death in Australia.

Actinogen is fully funded for its pivotal Phase II clinical trial. 

Positive results from this Phase II trial could see a significant partnering potential given the interest in alzheimers from pharmaceutical companies. 

In late September, 24 million shares were traded in the company in one day.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 06 Oct 2015 15:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147784/actinogen-medical-on-track-with-alzheimer-drug-trial-64926.html
<![CDATA[News - Actinogen Limited readies to reveal clinical data ]]> http://www.proactiveinvestors.com.au/companies/news/147783/actinogen-limited-readies-to-reveal-clinical-data-64787.html Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.

The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.

The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 28 Sep 2015 14:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147783/actinogen-limited-readies-to-reveal-clinical-data-64787.html
<![CDATA[News - Actinogen Medical raises $10M for Alzheimer’s drug trial ]]> http://www.proactiveinvestors.com.au/companies/news/147782/actinogen-medical-raises-10m-for-alzheimers-drug-trial-61956.html Sydney based Actinogen Medical (ASX:ACW) has raised $10.0 million to further a trial of its very promising drug to fight Alzheimer’s disease.

The funds were raised in a placement which saw heavy investor demand at an issue price of $0.095 per share.

The Phase 2 trial of its drug Xanamem™ is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

Xanamem blocks cortisol production which is a key plank in the fight against Alzheimer's disease to stop the disease at an early stage.

Excess cortisol is associated with memory loss and amyloid plaques, hallmarks of Alzheimer’s disease.

The capital raising will also be used to support the IND filing with US FDA.

A share purchase plan will also raise an additional $1 million.

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and families. At present, there is no viable cure for sufferers.

Alzheimer’s is now the second leading cause of death in Australia behind ischaemic heart disease.

Estimates by the American Alzheimer’s Association indicate that the direct healthcare cost of the disease was $US250 billion in 2013.

This is projected to rise to over $US1 trillion by 2050, outstripping the cost of treating all other diseases.

 

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 24 Apr 2015 11:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147782/actinogen-medical-raises-10m-for-alzheimers-drug-trial-61956.html
<![CDATA[News - Actinogen to raise capital for Phase II Alzhimer’s disease clinical study ]]> http://www.proactiveinvestors.com.au/companies/news/147781/actinogen-to-raise-capital-for-phase-ii-alzhimers-disease-clinical-study-61916.html Actinogen (ASX:ACW) is progressing development of its novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders.

The company has now been granted an ASX trading halt in relation to a capital raising for a Phase II study in Alzheimer’s dementia.

This will last until the earlier of the announcement being made or the start of trade on Friday, 24th April 2015.

Actinogen’s lead drug candidate Xanamem is being developed as a new therapy for Alzheimer’s disease.

Earlier this month, the company successfully dosed the second cohort of Phase I trial participants with 20mg of Xanamem.

This led to its being granted approval to escalate the dose to 35mg for the final cohort.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 22 Apr 2015 16:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147781/actinogen-to-raise-capital-for-phase-ii-alzhimers-disease-clinical-study-61916.html
<![CDATA[News - Actinogen extends Alzheimer's drug patent protection in Europe ]]> http://www.proactiveinvestors.com.au/companies/news/147780/-actinogen-extends-alzheimers-drug-patent-protection-in-europe-61713.html Actinogen (ASX:ACW) has received official notification to grant from the European Union Patent Office for patent application 11709770.9.

This protects the use ACW's Xanamem™ for use in Alzheimer’s dementia and other related diseases associated with the inhibition of 11-beta-hydroxysteroid dehydrogenase.

Importantly this European patent further extends the comprehensive cover to 2031.

The claims in these patents cover method-to-treat for various diseases beyond Alzheimer’s dementia such as type 2 diabetes and obesity, hypertension, and cardiovascular disorders.

They also cover central nervous system disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease, post-traumatic stress disorder, depression, and schizophrenia.

Xanamem™ inhibits an enzyme that reduces cortisone to the active hormone cortisol, which activates glucocorticoid receptors.

The cost of Alzheimer’s treatment in the US alone was estimated to be US$250 billion last year by the American Alzheimer’s Association.

The drug works by blocking the development of cortisol - the stress hormone - in the hippocampus, the area of the brain most affected by Alzheimer’s disease.

There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death, which are the hallmarks of Alzheimer’s disease.

Actinogen is currently completing a second Phase I study on Xanamem™ with results expected mid-2015.

It is set to start a Phase II Alzheimer’s dementia study in early 2016 which is planned to run in Australia, New Zealand, Europe and the USA, under a US Food & Drug Administration approved Investigational New Drug.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 13 Apr 2015 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147780/-actinogen-extends-alzheimers-drug-patent-protection-in-europe-61713.html
<![CDATA[News - Actinogen confirms safety of Alzheimer's drug ]]> http://www.proactiveinvestors.com.au/companies/news/147779/actinogen-confirms-safety-of-alzheimers-drug-61400.html Actinogen (ASX:ACW) has received confirmation from an independent Dose Escalation Committee that its lead drug candidate, Xanamem, when dosed at 10mg, satisfies safety, tolerability and pharmacokinetic metrics.

This now allows for a dose escalation to 25mg for the next cohort of 8 participants.

Actinogen expects the next cohort to be dosed in late March. The clinical trial program continues to execute on time and on budget.

Xanamem is being developed as a new therapy for Alzheimer’s disease, a condition with a multi-billion dollar market potential.

The cost of Alzheimer’s treatment in the US alone was estimated to be US$250 billion last year by the American Alzheimer’s Association.

This cost is estimated to increase to US$1 trillion by 2050, outstripping the cost of treating all other diseases.

Xanamem’s novel mechanism of action sets it apart from existing Alzheimer’s treatments.

It works by blocking the production of the stress hormone cortisol in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease.

There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 24 Mar 2015 11:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147779/actinogen-confirms-safety-of-alzheimers-drug-61400.html
<![CDATA[News - Actinogen Limited to reveal acquisition and raising ]]> http://www.proactiveinvestors.com.au/companies/news/147778/actinogen-limited-to-reveal-acquisition-and-raising-57159.html Actinogen Limited (ASX:ACW) is preparing to reveal details of an acquisition, along with a capital raising.

The ASX has granted the company a trading halt, with its shares placed in pre-open.

Currently, one of Actinogen's lead therapeutic programs is focused on discovering and developing drugs to treat brain cancer and potentially other oncological diseases by the targeted killing of cancer stem cells (CSCs).

In February the company entered into a research agreement with Curtin University to conduct further studies on the company’s CSC Project.

Cancer stem cells have been reported in many human tumours and are classified as a highly tumorigenic subpopulation that drives tumour formation, proliferation and metastasis.

CSCs share a variety of biological properties with normal stem cells such as capacity for self-renewal and propagation of differentiated progeny.

The company had $1.1 million in cash at the end of the June 2014.

The halt will remain in place until the opening of trade on Thursday 28th August 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 26 Aug 2014 14:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147778/actinogen-limited-to-reveal-acquisition-and-raising-57159.html
<![CDATA[News - Actinogen isolates demonstrate anti-cancer properties ]]> http://www.proactiveinvestors.com.au/companies/news/147777/actinogen-isolates-demonstrate-anti-cancer-properties-55605.html Actinogen (ASX:ACW) has received positive initial results from its Cancer Stem Cell project with several isolates from its library demonstrating the ability to counteract the formation of tumours.

Researchers at Curtin University tested 11 isolates from the company’s library on their ability to demonstrate antitumorigenic effects by affecting the viability of cancer stem cells in selected glioblastoma cell lines.

Glioblastoma is considered as the most aggressive type of brain cancer.

Cancer cell populations were reduced by about 80% by two of the isolates, which are consistent with previous internal results and supports the strong anti-cancer activity of some of the actinomycetes isolates.

CSC sphere disruption, cell anchorage, and cell death were observed with different isolates for the CSCs across all 4 cell lines.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 13 Jun 2014 16:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147777/actinogen-isolates-demonstrate-anti-cancer-properties-55605.html
<![CDATA[News - Actinogen to commence trials on key antibiotic project in WA ]]> http://www.proactiveinvestors.com.au/companies/news/147776/actinogen-to-commence-trials-on-key-antibiotic-project-in-wa-52760.html Perth-based Actinogen (ASX:ACW) will commence further trials on its antibiotic research project at its new laboratory premises at Murdoch University’s State Agricultural Biotechnology Centre, Western Australia.

Antibiotic-resistant bacteria are becoming an increasing problem, with research and investment directed to discovering new effective agents and treatments.

In fact, the death rate for patients with serious infections treated in hospitals is about twice that in patients with infections caused by non-resistant bacteria.

A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci (VRE) and Clostridium difficile.

The antibiotic research program was identified as a key component of the Company’s future strategy in the drug development area.

Actinogen aims to discover and isolate a group of environmental bacteria known as the Actinomycetes.

Actinogen owns a private existing database of over 6000 actinomycetes. Previously, the library has been screened to identify actinomycetes able to produce compounds with antimicrobial activity against resistant strains.

The actinomycetes are then tested for activity against the MRSA panel, VRE, Candida spp., Pseudomonas aeruginosa and the anaerobic pathogen Clostridium difficile.

These testing panels consist of clinical isolates of microorganisms that have developed serious antibiotic resistance patterns and can therefore be used to increase the likelihood of finding new antibiotics.

If the isolation of the active compound is successful, it may be sent to an independent laboratory for further characterisation.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 12 Feb 2014 18:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147776/actinogen-to-commence-trials-on-key-antibiotic-project-in-wa-52760.html
<![CDATA[News - Actinogen lands fully funded bioethanol project collaboration ]]> http://www.proactiveinvestors.com.au/companies/news/147775/actinogen-lands-fully-funded-bioethanol-project-collaboration-51380.html Actinogen Limited (ASX: ACW) has entered into a collaborative and royalty agreement with Leaf Energy (ASX: LER) for its bioethanol project.

Leaf will fund further studies in the bioethanol project, where strains of actinomycetes produce enzymes such as cellulase which break down cellulose from plant material, papers and industrial waste biomass.

These enzymatic reactions are an important step in the production of second generation bioethanols.

An independent study by the CSIRO has confirmed Actinogen's ability to produce cellulases, and was shown to be more active than its comparative commercially available preparations.

Actinogen’s process can potentially be more cost effective than current methods, and avoid the need to rely on human food stocks as the source material.

The traditional method of producing cellulase is usually performed in an anaerobic environment at high temperatures, which requires infrastructure capital.

Actinogen can produce cellulase in an aerobic environment at room temperature, which may significantly lower costs.

Leaf Energy’s glycerol pretreatment process is complementary, using the cheap, recyclable glycerol in a simple process to break down plant matter into lignin, cellulose and hemicellulose at low temperature and pressure.

The cellulose and hemicellulose are then available for conversion to sugars using enzymatic hydrolysis and those sugars can then be converted to advanced biofuels, bioplastics and green chemicals

On success of the initial trial, Leaf will have the option to contribute further funding towards additional trials to explore the potential synergy of other actinomycetes, specifically those identified to produce lignase and shikimic acid, for the use in its biomass processes.

Actinogen will grant leaf the rights use any methods of production solely developed as part of the collaborative process, in return for a net profit royalty on Leaf's future licensing arrangements, which are confidential in nature.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 23 Dec 2013 10:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147775/actinogen-lands-fully-funded-bioethanol-project-collaboration-51380.html
<![CDATA[News - Actinogen Limited wraps up share consolidation, continuing bioactive compound research ]]> http://www.proactiveinvestors.com.au/companies/news/147774/actinogen-limited-wraps-up-share-consolidation-continuing-bioactive-compound-research-51028.html Actinogen Limited (ASX: ACW) has now completed the consolidation of the Company’s securities on a 1:2 basis, and now has around 51.1 million shares on issue, and 9.1 million 30/9/2015 options exercisable at $0.40 each.

Trading on a normal T+3 settlement basis will kick off next Tuesday the 17th December 2013.

Actinogen has a unique company aim to identify and isolate soil microorganisms, known as actinomycetes, which are capable of producing bioactive compounds of commercial value.

There is the potential for actinomycetes to degrade industrial wastes such as oils, tar, domestic and industrial waste, and the rehabilitation of oil spills.

Actinogen is looking to collaborate with groups nationally and internationally in the development of technology that is synergistic with, or that could perhaps utilise, its current actinomycetes research projects and intellectual property.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 10 Dec 2013 13:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147774/actinogen-limited-wraps-up-share-consolidation-continuing-bioactive-compound-research-51028.html
<![CDATA[News - Actinogen to apply tax refund to laboratory relocation, re-establishing research team ]]> http://www.proactiveinvestors.com.au/companies/news/147773/actinogen-to-apply-tax-refund-to-laboratory-relocation-re-establishing-research-team-50663.html Actinogen (ASX: ACW) has received a $146,954 tax refund from the Australian Government’s Research and Development Tax Incentive Program.

Proceeds will be used to relocate its laboratory to new facilities, re-establish its scientific research team and working capital requirements for the continuation of the research and development of its focal projects.

Actinogen's aim is to identify and isolate soil microorganisms, known as actinomycetes, which are capable of producing bioactive compounds of commercial value.

These include bacterial antibiotics, anti-viral agents, anti-tumour agents, antifungal agents and immunosuppressive agents that are used for humans, animals and in agriculture.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 29 Nov 2013 08:20:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147773/actinogen-to-apply-tax-refund-to-laboratory-relocation-re-establishing-research-team-50663.html
<![CDATA[News - Actinogen to recapitalise with $1.6 million cash injection ]]> http://www.proactiveinvestors.com.au/companies/news/147772/actinogen-to-recapitalise-with-16-million-cash-injection-47845.html Actinogen (ASX:ACW) has accepted an offer from Otsana Capital to recapitalise, allowing repayment of all outstanding debts with sufficient cash remaining to support its near-term business objectives.

Actinoigen has recently focused on a plant growth hormone and will consider field trials with a view to delivering a product saleable to farmers and other plant producers.

A placement is proposed of 300 million ACW shares at $0.005 to raise $1,500,000, together with 100 million unlisted options to acquire additional shares at $0.005 within 4 years from date of issue.

Otsana will make available an unsecured loan of up to $100,000 in advance at 15% interest, payable quarterly in arrears via conversion to shares, and is to nominate two new directors to the board of Actinogen.

The board of directors supports Otsana's proposal and intend to unanimously recommend the offer to shareholders.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Actinogen (ASX:ACW) has accepted an offer from Otsana Capital to recapitalise, allowing repayment of all outstanding debts with sufficient cash remaining to support its near-term business objectives.

Actinoigen has recently focused on a plant growth hormone and will consider field trials with a view to delivering a product saleable to farmers and other plant producers.

A placement is proposed of 300 million ACW shares at $0.005 to raise $1,500,000, together with 100 million unlisted options to acquire additional shares at $0.005 within 4 years from date of issue.

Otsana will make available an unsecured loan of up to $100,000 in advance at 15% interest, payable quarterly in arrears via conversion to shares, and is to nominate two new directors to the board of Actinogen.

The board of directors supports Otsana's proposal and intend to unanimously recommend the offer to shareholders.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 11 Sep 2013 15:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147772/actinogen-to-recapitalise-with-16-million-cash-injection-47845.html
<![CDATA[News - Actinogen to begin plant growth hormone trials ]]> http://www.proactiveinvestors.com.au/companies/news/147771/actinogen-to-begin-plant-growth-hormone-trials--41336.html Actinogen (ASX: ACW) will tomorrow begin independent pot trials to further test the performance of the previously discovered actinomycetes that produce plant growth hormones.

The trials will test the effectiveness of the growth hormones on wheat and peas, specifically measuring the amount of root, leaf and stem growth. 

Actinogen completed initial pot trials on a series of actinomycetes in 2010 and 2011 which showed significant increased root growth and leaf and stem growth.

The new independent trials are being run for around six to seven weeks, with results to be available on conclusion of the trials.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 27 Mar 2013 14:50:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147771/actinogen-to-begin-plant-growth-hormone-trials--41336.html
<![CDATA[News - Actinogen makes landmark discovery of possible pathogenic fungi killer ]]> http://www.proactiveinvestors.com.au/companies/news/147770/actinogen-makes-landmark-discovery-of-possible-pathogenic-fungi-killer--29080.html Actinogen (ASX: ACW) has made a discovery that could have potential commercial applications in the elimination of pathogenic fungi that kills crops, grains, plantations and possibly even dieback in forests.

The company has isolated, from Western Australian soil, a small series of actinomycetes that have the ability to synthesize volatile bioactive molecules (polyenes).

The actinomycetes producing polyenes may be able to be used to naturally biofumigate soils to stop the infection of plants and grasses with pathogenic fungi.

Polyenes are a group of compounds often produced by microorganisms. These compounds can be volatile or not and have been shown to exhibit bacterial antibiotic properties over a wide range of microorganisms.

They are used as human and animal antibiotics and plants directed against pathogens including bacteria and fungi.

Actinogen has applied for an Australian provisional patent covering the discovery and is now seeking commercial partners.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Mon, 21 May 2012 12:40:00 +1000 http://www.proactiveinvestors.com.au/companies/news/147770/actinogen-makes-landmark-discovery-of-possible-pathogenic-fungi-killer--29080.html
<![CDATA[News - Actinogen readies to begin commercialisation of bioethanol product ]]> http://www.proactiveinvestors.com.au/companies/news/147769/actinogen-readies-to-begin-commercialisation-of-bioethanol-product-26663.html Actinogen (ASX: ACW) has appointed an independent expert to compile a report on the commercialisation of the company’s bioethanol research program as it heads towards development.

The company has discovered how to make cellulase(s), which has been confirmed in scale at fermentation trials by the CSIRO.

During the company’s research program to develop cheaper production methods of biofuels, Actinogen discovered actinomycetes that produce cellulase(s) as a by-product when breaking down newspaper, brown paper and glycerol.

Independent tests conducted by the CSIRO confirmed that Actinogen can produce cellulase(s) in volumes of up to at least 10 litres.

Late last year, Actinogen identified a way of increasing the production of cellulase(s) by at least 37% by using a continuous infusion system with laboratory purity glycerol as a nutrient supply.

The company is moving to begin phases three and four of the proposed development strategy outlined by Dr Karne De Boer, a renewable energy engineer and managing director of Regenerate Industries.

Regenerate Industries is a Perth-based company that specialises in the development of biodiesel plants, bioenergy cogeneration plants and integrated systems based around renewable energy.

The company’s most recent project is a $500,000 biodeisel plant in Tasmania converting poppy seed oil into biodiesel.

Phase three of De Boer’s development strategy for Actinogen includes the quantification of sugar production, investigation with waste glycerol, and optimisation of bench top fermentations, which will determine the best conditions for building a test pilot plant.

Phase four includes the design, construction, operation and optimisation of a pilot plant and the development of a cost model for sugar production.

The pilot plant will use the enzymes created by Actinogen on biomass to produce sugars that can be used to ferment bioethanol.

The company will measure the sugars produced and determine whether its process can be used in commercial quantities.

Actinogen is considering two commercial pathways – developing a “black box” that takes substrate, such as waste glycerol or paper, and produces a cellulase rich liquid onsite for other developed bioethanol producers, or constructing its own bioethanol production facility.

]]>
Tue, 20 Mar 2012 15:30:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147769/actinogen-readies-to-begin-commercialisation-of-bioethanol-product-26663.html
<![CDATA[News - Actinogen increases production of bioethanol product by 37% ]]> http://www.proactiveinvestors.com.au/companies/news/147768/actinogen-increases-production-of-bioethanol-product-by-37--23181.html Actinogen (ASX: ACW) has identified a way of increasing the production of cellulase(s), a product crucial in making bioethanol, by at least 37% by using a continuous infusion system with laboratory purity glycerol as a nutrient supply.

Last month, the company announced it has discovered how to make cellulase(s), which has been confirmed in scale at fermentation trials by the CSIRO.

During the company’s research program to develop cheaper production methods of biofuels, Actinogen discovered actinomycetes that produce cellulase(s) as a by-product when breaking down newspaper, brown paper and glycerol.

Independent tests conducted by the CSIRO confirmed that Actinogen can produce cellulase(s) in volumes of up to at least 10 litres.

This system can now be optimised through the continuous culture production of cellulase(s) potentially from the glycerol by-product of the biodiesel industry.

Importantly, with continuing success in its research, Actinogen is now ready to expand its research program to industrial based assessment and pilot scale development.

The company will continue its research into producing cellulase(s) from using waste glycerol from the biodiesel industry, waste papers, green waste and other domestic wastes to produce cheaper biofuels.

]]>
Thu, 08 Dec 2011 08:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147768/actinogen-increases-production-of-bioethanol-product-by-37--23181.html
<![CDATA[News - Actinogen discovers key bioethanol ingredient, readies itself for pilot scale development ]]> http://www.proactiveinvestors.com.au/companies/news/147767/actinogen-discovers-key-bioethanol-ingredient-readies-itself-for-pilot-scale-development-21805.html Actinogen (ASX: ACW) has discovered how to make cellulase(s), a product crucial in making bioethanol, which has been confirmed in scale at fermentation trials by the CSIRO.

During the company’s research program to develop cheaper production methods of biofuels, Actinogen discovered actinomycetes that produce cellulase(s) as a by-product when breaking down newspaper, brown paper and glycerol.

Independent tests conducted by the CSIRO confirmed that Actinogen can produce cellulase(s) in volumes of up to at least 10 litres.

Currently, most cellulase(s) production by a bio-cellulase producing system often uses an anaerobic environment and high temperatures in the producing system. This makes bio-cellulase(s) production costly.

Actinogen can produce cellulase(s) from the activity of particular actinomycetes when the actinomycetes are exposed to brown paper, newspaper and/or glycerol.

The cellulase(s) is produced in an aerobic environment and does not require a high temperature system. Producing cellulase(s) aerobically and at ambient temperatures can potentially lower production costs.

Significantly, Actinogen’s process of producing cellulase(s) does not require the use of foodstuffs, eliminating the need to use crops and food in the production of bioethanol.

The company is ready to expand its research program to industrial based assessment and pilot scale development.

]]>
Wed, 09 Nov 2011 12:52:00 +1100 http://www.proactiveinvestors.com.au/companies/news/147767/actinogen-discovers-key-bioethanol-ingredient-readies-itself-for-pilot-scale-development-21805.html